Literature DB >> 11289111

RGD-Tachyplesin inhibits tumor growth.

Y Chen1, X Xu, S Hong, J Chen, N Liu, C B Underhill, K Creswell, L Zhang.   

Abstract

Tachyplesin is an antimicrobial peptide present in leukocytes of the horseshoe crab (Tachypleus tridentatus). In this study, a synthetic tachyplesin conjugated to the integrin homing domain RGD was tested for antitumor activity. The in vitro results showed that RGD-tachyplesin inhibited the proliferation of both cultured tumor and endothelial cells and reduced the colony formation of TSU prostate cancer cells. Staining with fluorescent probes of FITC-annexin V, JC-1, YO-PRO-1, and FITC-dextran indicated that RGD-tachyplesin could induce apoptosis in both tumor and endothelial cells. Western blotting showed that treatment of cells with RGD-tachyplesin could activate caspase 9, caspase 8, and caspase 3 and increase the expression of the Fas ligand, Fas-associated death domain, caspase 7, and caspase 6, suggesting that apoptotic molecules related to both mitochondrial and Fas-dependent pathways are involved in the induction of apoptosis. The in vivo studies indicated that the RGD-tachyplesin could inhibit the growth of tumors on the chorioallantoic membranes of chicken embryos and in syngenic mice.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11289111

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

Review 1.  Tumor cell membrane-targeting cationic antimicrobial peptides: novel insights into mechanisms of action and therapeutic prospects.

Authors:  Amy A Baxter; Fung T Lay; Ivan K H Poon; Marc Kvansakul; Mark D Hulett
Journal:  Cell Mol Life Sci       Date:  2017-08-02       Impact factor: 9.261

2.  Targeted delivery of a proapoptotic peptide to tumors in vivo.

Authors:  Sandrine Dufort; Lucie Sancey; Amandine Hurbin; Stéphanie Foillard; Didier Boturyn; Pascal Dumy; Jean-Luc Coll
Journal:  J Drug Target       Date:  2010-12-24       Impact factor: 5.121

Review 3.  Issues related to targeted delivery of proteins and peptides.

Authors:  Yingjuan Lu; Jun Yang; Emanuela Sega
Journal:  AAPS J       Date:  2006-07-21       Impact factor: 4.009

4.  A novel targeted therapy of Leydig and granulosa cell tumors through the luteinizing hormone receptor using a hecate-chorionic gonadotropin beta conjugate in transgenic mice.

Authors:  Gabriel Bodek; Susanna Vierre; Adolfo Rivero-Müller; Ilpo Huhtaniemi; Adam J Ziecik; Nafis A Rahman
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

Review 5.  Studies on anticancer activities of antimicrobial peptides.

Authors:  David W Hoskin; Ayyalusamy Ramamoorthy
Journal:  Biochim Biophys Acta       Date:  2007-11-22

Review 6.  Integrins in prostate cancer progression.

Authors:  Hira Lal Goel; Jing Li; Sophia Kogan; Lucia R Languino
Journal:  Endocr Relat Cancer       Date:  2008-06-04       Impact factor: 5.678

7.  Navigare necessere est. Improved navigation would help to solve two crucial problems in modern drug therapy: toxicity and precise delivery.

Authors:  Sandra Kraljevic; Kresimir Pavelic
Journal:  EMBO Rep       Date:  2005-08       Impact factor: 8.807

8.  Systemic Delivery of Tumor-Targeted Bax-Derived Membrane-Active Peptides for the Treatment of Melanoma Tumors in a Humanized SCID Mouse Model.

Authors:  Anastassia Karageorgis; Michaël Claron; Romain Jugé; Caroline Aspord; Fabien Thoreau; Claire Leloup; Jérôme Kucharczak; Joël Plumas; Maxime Henry; Amandine Hurbin; Pascal Verdié; Jean Martinez; Gilles Subra; Pascal Dumy; Didier Boturyn; Abdel Aouacheria; Jean-Luc Coll
Journal:  Mol Ther       Date:  2017-02-01       Impact factor: 11.454

9.  Artificial neural network study on organ-targeting peptides.

Authors:  Eunkyoung Jung; Junhyoung Kim; Seung-Hoon Choi; Minkyoung Kim; Hokyoung Rhee; Jae-Min Shin; Kihang Choi; Sang-Kee Kang; Nam Kyung Lee; Yun-Jaie Choi; Dong Hyun Jung
Journal:  J Comput Aided Mol Des       Date:  2009-12-18       Impact factor: 3.686

10.  The anticancer activity of lytic peptides is inhibited by heparan sulfate on the surface of the tumor cells.

Authors:  Bodil Fadnes; Oystein Rekdal; Lars Uhlin-Hansen
Journal:  BMC Cancer       Date:  2009-06-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.